NNNN | Ticker Profile - Titan Protect

NNNN

Anbio Biotechnology

Healthcare · Medical Instruments & Supplies · NGM

$22.99

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.4B

Total market value of the company

Trailing P/E

218.60

Expensive — high growth expected

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

+73.9%

Year-over-year revenue change

Profit Margin

74.1%

How much profit the company keeps from each dollar of revenue

ROE

27.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About Anbio Biotechnology

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits. It serves over-the-counter, point-of-care testing, and laboratory markets. Anbio Biotechnology was incorporated in 2021 and is based in Frankfurt am Main, Germany.

https://www.anbiobiotechnology.com

Country: Germany Employees: 27 Industry: Medical Instruments & Supplies

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

1.677

Excellent risk-adjusted returns

Kelly Fraction

0.1458

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

4.035

Returns exceed worst-case losses — strong risk profile

Annual Return

308.3%

Historical annualised return based on price data

Max Drawdown

-76.4%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$55.65

59% below the year high

52W Low

$7.67

200% above the year low

Avg Volume

29,550

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

0.2%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$0.15

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

344.31

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

177.13

Like current ratio but excludes inventory — stricter test

Gross Margin

87.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

59.1%

Profit from core operations before interest and tax

Free Cash Flow

$-9,605,703

Negative — the business is spending more than it generates

Revenue (TTM)

$9M

Total revenue over the last 12 months

Net Income

$6M

Profitable — the bottom line is positive

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go